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HPV infection is a direct cause of neoplasia and malignancy. Cellular immunologic activity against cells expressing HPV E6
and E7 is suﬃcient to eliminate the presence of dysplastic or neoplastic tissue driven by HPV infection. Live attenuated Listeria
monocytogenes- (Lm-) based immunotherapy (ADXS11-001) has been developed for the treatment of HPV-associated diseases.
ADXS11-001 secretes an antigen-adjuvant fusion (Lm-LLO) protein consisting of a truncated fragment of the Lm protein
listeriolysin O (LLO) fused to HPV-16 E7. In preclinical models, this construct has been found to stimulate immune responses and
aﬀect therapeutic outcome. ADXS11-001 is currently being evaluated in Phase 2 clinical trials for cervical intraepithelial neoplasia,
cervical cancer, and HPV-positive head and neck cancer. The use of a live attenuated bacterium is a more complex and complete
method of cancer immunotherapy, as over millennia Lm has evolved to infect humans and humans have evolved to prevent and
reject this infection over millennia. This evolution has resulted in profound pathogen-associated immune mechanisms which are
genetically conserved, highly eﬃcacious, resistant to tolerance, and can be uniquely invoked using this novel platform technology.
1.Introduction
It has been estimated that HPV infection accounts for
approximately 5 percent of all cancers worldwide [1].
Persistent HPV infections are now recognized as the cause
of essentially all cervical cancers. In 2010, it was estimated
that about 12,000 women in the United States would be
diagnosed with this type of cancer and more than 4,000
would die from it. Cervical cancer is diagnosed in nearly half
a million women each year worldwide, claiming a quarter
of a million lives annually. HPV infection also causes some
cancers of the anus, vulva, vagina, and penis [1]. Sexually
transmitted HPV infections are very common and have
peak prevalence between the ages of 18 and 30. Most of
these infections resolve spontaneously, but, in 10–20% of
women, these infections remain persistent and are at risk of
progression to Grade 2/3 cervical intraepithelial neoplasm
(CIN) and eventually to invasive cancer of the cervix (ICC).
CINs are genetically unstable lesions with a 30–40% risk of
progressiontoICC.Ifleftuntreated,theyformaspectrumof
increasing cytological atypia, ranging from low-grade CIN 1
to high-grade CIN 3; the latter are caused almost exclusively
by high-risk HPVs, namely, HPV 16 and 18.
Oral HPV infection causes some cancers of the orophar-
ynx (the middle part of the throat, including the soft
palate, the base of the tongue, and the tonsils) [1–5].
HPV is associated with 20–50% of oral squamous cell
carcinomas [6], and the incidence is dramatically increasing.
HPV has also been implicated as having a role in certain
colorectal cancers and lung cancers although the association
is somewhat controversial.
2. HPV as a Target for Immunotherapy
HPV is a double-stranded, circular DNA virus devoid of an
envelope. Depending upon the strain, its genome contains
either six or seven early proteins (E1, E2, E4, E5, E6, E7,
and E8) and 2 structural proteins which appear later (L1
and L2). Infection with the virus occurs in replicating, diﬀer-
entiating basal epithelial cells. As keratinocytes diﬀerentiate
and mature, the expression of viral genes results in viral
protein production until terminally diﬀerentiated surface
cells express the late proteins, the viral capsid is assembled,
and the virus is shed. HPV-induced cancer can occur when
viral DNA integrates into the genome of the host, typically
with the deletion of the genes E2, E4, E5, L1, and L2. The2 Journal of Oncology
Table 1: Modiﬁcation of Lm-LLO-based immunotherapy for HPV-associated cervical cancer.
Vaccine name Design Strain modiﬁcation Antigen Ref.
ADXS11-001 (Lm-LLO-E7) Plasmid prfA− E7, HPV-16 [7]
Lm-PEST-E7 Plasmid prfA− E7, HPV-16 [8]
Lm-ActA-E7 Plasmid prfA− E7, HPV-16 [8]
Lm-dd-TV Plasmid dal−dat− E7, HPV-16 [9]
loss of the viral E2 gene, which is a transcriptional inhibitor,
leads to the upregulation of two oncoproteins from genes
E6 and E7. The viral oncoprotein E6 complexes with the
tumor inhibitor gene p53 and the oncoprotein E7 complexes
with the tumor suppressor protein retinoblastoma (pRb)
[10], disrupting cell cycle regulation and leading to genomic
instability and subsequent neoplasia [11].
HPV-associated neoplasia is one of the most clear-cut
situations in medicine where infection with an exogenous
agent (a virus) is a direct cause of neoplasia and malignancy.
Cellular immunologic activity against cells expressing HPV
E6 and E7 is suﬃcient to eliminate the presence of dysplastic
or neoplastic tissue driven by HPV infection. The variable
but signiﬁcant rate of spontaneous remission is felt to be due
to immunologic recognition of the HPV proteins expressed
in transformed cells and higher numbers of CD8+ cells
and a higher ratio of CD8+/FOXp3 cells inﬁltrating the
dysplastic tissue [4, 12–14]. An immunologic stimulus may
be required to overcome tolerance that has developed to the
HPV-transformed dysplastic cells.
3. Use of Lm-LLO Immunotherapy for
HPV-AssociatedDisease
A therapeutic change in the ratio of CD8+ TIL to Tregs
has been observed as a result of the administration of
Lm-LLO immunotherapies in a variety of models [15–18].
Lm-LLO-E7 (ADXS11-001) has been found in a variety of
preclinical models to stimulate immune responses and aﬀect
therapeutic outcomes and is currently in clinical trials.
Just such a live attenuated Listeria monocytogenes-( Lm-)
based immunotherapy (ADXS11-001) has been developed
for the treatment of HPV-associated diseases by Advaxis, Inc.
ADXS11-001 secretes an antigen-adjuvant fusion (Lm-LLO)
protein consisting of a truncated fragment of the Lm protein
listeriolysin O (LLO) fused to HPV16-E7. A Phase 1 study
has been completed with ADXS11-001 [19] and 4 Phase 2
clinical trials are active or about to be initiated.
Lm-LLO immunotherapies have multiple simultaneous
mechanisms of action that can summate in a therapeutic
response [20]. Lm stimulates innate immunity and infects
APC where it naturally cross-presents to stimulate both
arms of the adaptive immune system resulting in activated
CD4+ and CD8+. These agents reduce intratumoral Tregs
and MDSC, but not those in spleen or lymph nodes. They
can stimulate the maturation of immature immune cells to
terminally diﬀerentiated eﬀector cells and shift the kinetics
of bone marrow to produce increased numbers of myeloid
cells. Eﬀects have been observed in vascular endothelial cells
to facilitate chemotaxis and the extravasation of activated
immune cells. Lm is an entirely cellular immune stimu-
lating agent, and antibody formation of the type that can
inactivate viruses does not occur with Lm. Interestingly,
consolidated immune memory responses to Lm antigens
have been observed to occur rapidly, with correlates of
immune memory to Lm occurring as early as 5 hours after
exposure [21].
The use of a live attenuated bacterium is a diﬀerent
way to approach cancer immunotherapy than those based
upon synthetic chemistry or antibody-based agents. It is
more complex, as Lm has evolved to infect humans and
humanshaveevolvedtopreventandrejectthisinfectionover
millennia.Thisevolutionhasresultedinprofoundpathogen-
associated immune mechanisms which are genetically con-
served, highly eﬃcacious, and can be uniquely invoked using
this novel platform technology.
4.Listeria monocytogenes (Lm):
A Potent Vector for Immunotherapy for
Neoplastic andInfectiousDisease
Previous studies have shown that bioengineered Lm is a
potent vector not only for immunotherapy of cancer but also
for infectious diseases [20, 22]. This makes HPV infections
and consequently HPV-associated cancers a prime target for
therapy. With Lm-LLO-based immunotherapy, it is possible
to (a) eradicate tumors induced by HPV and (b) prevent
reoccurrence of the tumor. Advaxis in collaboration with
Yvonne Paterson’s Lab (University of Pennsylvania School
of Medicine) has developed various vectors expressing the
tumor-speciﬁc antigens (TSAs) that target HPV-induced
cancer as described in Table 1. Preclinical studies using
diﬀerent plasmid backbones for delivering E7 show similar
antitumor therapeutic eﬃcacy in all the vectors described
in Table 1. The ADXS11-001 (Lm-LLO-E7) was selected for
human studies as it was extensively studied and tested in
preclinical settings. Furthermore, ADXS11-001 pathogenic-
ity was attenuated by 104 to 105 logs, compared to the wild-
type Lm parent strain 10403S, thus increasing its safety for
clinical use.
Various methods of bioengineering allow Lm to express
TSA on the plasmid or in the genome via chromosomal
insertion [23, 24]. At Advaxis, two complementation mech-
anisms have been designed for the in vivo retention of
plasmids in attenuated bacterial strains. One strain is a prfA
deletion mutant which is avirulent due to the absence of the
master virulence regulating protein PrfA, rendering it unable
to escape the phagolysosome, but the intracellular growthJournal of Oncology 3
ability is restored through the complementation of PrfA on
a plasmid. This complementation ensures in vivo retention
of the plasmid, but for in vitro manipulation antibiotic resis-
tance markers such as chloramphenicol resistance gene were
used [7, 8]. Another backbone is a mutant strain defective
for D-alanine synthesis, which is essential for bacterial cell
wall synthesis. Survival of Lm strain deﬁcient in dal and dat
genes depends upon the plasmid-based complementation of
the dal gene. To eliminate the possibility of recombination of
dal gene present in the plasmid and the Lm genome, Bacillus
subtillis dal gene was used for complementation of in vivo
and in vitro growth. This complementation not only creates
an antibiotic-marker-free plasmid delivery system but also
attenuates the vector by 0.5 to 1 log [9]. ADXS11-001 with
theprfAdeletionwasfoundtobeclearedbySCIDmiceusing
innate immunity alone [20], and the clearance kinetics of the
dal dat demonstrated clearance within 72 hours. A highly
attenuated Lm dal− dat− actA− (LmddA) backbone was
created at Advaxis [24], which is cleared rapidly in vivo and
contains an antibiotic-marker-free plasmid for expression of
TSA, which is strong candidate for immunotherapy in the
clinic. Similar in vivo clearance of LmddA strain in both
normal and interferon-gamma knockout mice demonstrates
that this strain is highly attenuated and safe for clinical use.
5. LLO: An Adjuvantfor Immunotherapy
Listeriolysin O is a hemolytic, thiol-activated, cholesterol-
dependent pore-forming protein which is essential for
intracellular escape of Lm from the phagolysosome [25].
Recent advances in immunology have resulted in a number
of potential adjuvant candidates that are able to modulate
the immune response in a more controlled and speciﬁc
manner [26]. These adjuvants modulate and target speciﬁc
immune components, such as activation of diﬀerent cells,
receptors, or signaling pathways. [26]. Advaxis studies show
that nonhemolytic LLO also harbors unique properties of
an adjuvant: (a) augments the eﬀects of “non-self-foreign”
antigens as do classical adjuvants, (b) breaks tolerance of
“self-/tumor-associated antigens,” (c) speciﬁcally activates
or augments functions involved in antitumor activity, (d)
regulates complex soluble mediators and their receptors to
optimize the antitumor activity, and (e) modulates signals
to activate diﬀerent arms of the immune systems for
antitumor activity. Gunn et al. engineered an LLO molecule
truncated at the C-terminal of the protein, which rendered
theLLOnonhemolytic[20].Neesonetal.[27]independently
reported that LLO has adjuvant properties when used in the
form of a recombinant protein vaccine. Fusion of LLO to
tumorantigensdeliveredbyothervaccinemodalities,suchas
viralvectors[28] and DNA vaccines [29], also enhances their
therapeutic eﬃcacy. These properties of recombinant LLO
positions it as an attractive adjuvant not only for breaking
local and peripheral immunological tolerance of tumors and
associatedantigensbutalsoformountinganantigen-speciﬁc
and antigen-coordinated anticancer immune response as
described followingly in mouse models for HPV-related
cancer.
6.IntracellularEventsandAntigen
Presentation of Lm-LLO-Ag (HPV)
Fusion Protein
As shown in Figure 1, attenuated Lm carrying the HPV
antigen fused to LLO can be phagocytized by antigen-
presenting cells, macrophages, and other cells [20, 30]. The
attenuated bacterial cells are taken up into the endosome
where they evoke a conserved pathogenic assault [31]a n d
redirect the tumor antigen [23]. The PEST-like sequence
of LLO is important as it has been shown to increase
antitumor eﬃcacy of Lm-based vectors expressing the fusion
protein LLO-PEST-E7 in HPV-16 immortalized tumors [8].
This process stimulates cell-mediated immune response
generating CD4+ cells and CD8+ T cells [20]. The fusion
of antigens to LLO facilitates the secretion of the antigen
[32] and increases antigen presentation [8] with a profound
inﬂuence on CD8+ T-cell activation [20, 33].
7.In Vivo Response toLm-LLO-Ag (HPV)
Fusion ProteinandCellular Eventsin
the Tumor Environment
An in vivo response to Lm-LLO-Ag (HPV) fusion protein
induces several immune functions which are well coordi-
nated to break the local and peripheral tolerance to tumor-
speciﬁcantigensandtoinitiateachainofantitumoractivities
utilizing various soluble mediators and cells as shown in
Figure 2. LLO is a potent inducer of inﬂammatory cytokines,
such as IL-6, IL-8, IL-12, IL-18, TNF-α,I F N - γ,a n dG M -
CSF; nitric oxide, chemokines, as well as costimulatory
molecules that are important for innate and adaptive
immune responses [20, 35–37]. One example of the high
Th-1 cytokine-inducing activity of LLO is that protective
immunity to Lm can be induced with killed or avirulent
Lm when administered together with LLO, but not in the
absence of LLO [38]. Cytokines induced in macrophages in
the presence of LLO [39] in turn activate NK cells to release
IFN-γ [40].
8. Generation of Tumor-Antigen-Speciﬁc
Cytotoxic T Cells and
Regression of HPV-AssociatedTumors
Preclinical studies using a genetically engineered attenuated
strain of Lm expressing HPV-16 E7 demonstrated therapeu-
tic activity against E7-expressing tumors in animal models
[7]. Two Lm-LLO-based immunotherapy vectors, one of
which expresses the antigen HPV-16 E7 alone and one which
expresses E7 fused to a truncated form of LLO, showed
regression of the E7-expressing tumor, TC-1, established in
syngeneic C57BL/6 mice [7]. A lung epithelial cell line (TC-
1) immortalized with HPV-16 E6 and E7 and transformed
with the c-ras oncogene was used in these studies. Paterson
etal.haverecentlyutilizedanewrecombinantstrainofLthat
uses a multicopy episomal expression system (Lm-ActA-E7)4 Journal of Oncology
Figure 1: Schematic presentation of LLO-Ag (HPV) fusion protein processing and presentation in antigen-presenting cell (APC) by Listeria
monocytogenes. Advaxis in collaboration with Paterson et al. has developed human papilloma virus (HPV) and listeriolysin (LLO) fusion
proteins in Lm for immunotherapy [17, 22–24]. Upon injection in vivo,t h e s eLm are sequestered and engulfed by antigen-presenting cells
(APCs) such as dendritic cells [23, 24, 31]. The bacteria are engulfed by vacuoles where most of the Listeria are killed [18, 32]. The bacterium
while processing the tumor-associated antigen (HPV) and listeriolysin O (LLO) stimulates both arms of the adaptive immune system [20,
34].PartoftheantigenfromthevacuoleisprocessedviatheMHCclassIImoleculeswhichgenerateCD4+ Tc ells.Fi v et ot enper c entofthese
Lm escape into the cytosol with the assistance of the LLO where Listeria can undergo replication. The cytosolic HPV-LLO fusion protein
behaves as endogenous antigens. The HPV-LLO fusion protein undergoes ubiquitination, and it is processed via the proteasome [20]. The
resulting peptides are presented via the MHC class I molecules to generate CD8+ Tc e l l s[ 34]. These cells generate strong cell-mediated
immune responses. Lm also evokes a strong innate immune response which leads to generation of numerous mediators such as nitric oxide
which is involved in killing of the bacteria in the vacuoles and cytokines (such as TNF-β, IL-1, IL-18, IL-12, and IFNγ) which impart several
types of bystander eﬀects [20, 33, 35–37].
to secrete the HPV protein E7 fused to the Lm protein ActA
as shown in Figure 3.
The Lm-ActA-E7-based immunotherapy (but not
Lm-ActA-NP treated—used as nonspeciﬁc—controls) or
untreated controls caused 75% regression of the HPV-
positive tumors on day 20 when compared to the established
tumor on day 7. However, more than 90% regression of
tumors was observed when Lm-ActA-E7-induced tumor
reduction as compared to controls on day 28 (Figure 4).
Sewell et al. showed that antitumor activity of Lm-LLO-
based immunotherapy against E7 could also be seen in solid
tumors implanted in transgenic mice [8, 49]. This model
system also revealed the enhanced antitumor eﬃcacy of Lm-
LLO-based vectors expressing the fusion protein LLO-PEST-
E7 in HPV-16 immortalized tumors in syngeneic mice. It
should be noted that this immunotherapy has the potential
not only to cause tumor regression but also to prevent
the recurrence of tumors. A cytotoxic T-lymphocyte assay
revealed that administration of Lm-LLO-based vector caused
the generation of cytotoxic T cells speciﬁc for E7 (Figure 5).
9.Abilityof Lm-LLO-E7 to Induce CD8+
T-Cell Memory and Regression of
Established Tumors after
AntibioticAdministration
It should be noted that although Lm-LLO-based immuno-
therapy required a live attenuated bacteria as a carrier of
the fusion antigen, the bacteria may be killed shortly after
administrationbyantibiotictreatmentandtheimmunother-
apy will continue to demonstrate antitumor activity [20].Journal of Oncology 5
Figure 2:Hypotheticalrepresentationof invivoeﬀectsof Lm-LLO-basedimmunotherapy. Lm-LLO-basedimmunotherapyevokesacascade
of events in vivo which involves multiple cell types that may (a) regress existing tumors and (b) block tumor reoccurrence. The physiological
events associated with these potent therapeutic and prophylactic events include the following: (1) unusually rapid immunological memory
consolidation is generated with ﬁve-hour post-Listeria-based immunotherapy [41, 42]; (2) promotes bystander eﬀects via activation of
cytokines, chemokines, and/or their receptors regulate functions such as leukocytosis, memory, and listeriosis [20]; (3) stimulates synthesis
and maturation of immune myeloid cells by stimulating formation of myeloid cells and maturation of dendritic cells [39, 43, 44]; (4) guides
heterologous Ag (HPV) processing to generate antigen-speciﬁc CD4+ and CD8+ cells, via MHC class II and I pathways, respectively [34, 43];
(5) reduces Tregs and MDSC only in tumors and diminishes the tumor’s resistance to immune attack by antigen-speciﬁc cells [4, 14, 20, 45];
(6)boostsclass1and2armsofadaptiveimmuneresponsewhichgeneratesstrongcell-basedantitumorimmunity[9,24,30];(7)chemotaxis
and extravasation of activated immune cells is part of an innate immune response, involving the recruitment of nonspeciﬁc leukocytes into
tumors [34, 46, 47]; (8) PAMP-mediated innate immune stimulation facilitates processing of live Listeria which evokes the essential activity
of inﬂammasomes and innate immunity [48].
Experiments in mice by Baj´ enoﬀ et al. showed that Lm-
speciﬁc and Lm-nonspeciﬁc memory CD8+ T cells could be
observed within 6 hours of infection and with Lm burden
[41]. The Lm-speciﬁc and Lm-nonspeciﬁc memory CD8+
T cells were localized in red pulp of the spleen which
formed clusters around Lm-infected cells. Memory CD8+ T
cells produced inﬂammatory cytokines such as IFN-γ and
CCL3 nearby infected myeloid cells which are known to
be crucial for Lm killing. Corbin and Harty [42]r e p o r t e d
that Lm-infected mice treated with antibiotics at 24 hours
postinfection showed a robust increase in antigen-speciﬁc
CD4+ and CD8+ T cells similar to the response in controls
that did not receive the antibiotics. Furthermore, antibiotic
treatment did not alter secondary antigen-speciﬁc T-cell
expansion or protection with or without the antibiotics
[42]. These experiments demonstrate that development of
early CD4+ and CD8+ T cells show functional memory,
independentofprolongedinfectionorantigendisplayonday
28. Figure 6 shows that administration of antibiotics on day
3 posttreatment with ADXS11-001 has no eﬀect on eﬃcacy
as more than 90% tumor regression occurred in mice.
10.IntracellularMilieuinTumors
The presence of a complex immune suppressive network
in the tumor microenvironment includes, but is not lim-
ited to, (a) Tregs, (b) myeloid-derived suppressor cells
(MDSCs) along with their mediators (i.e., IL-10, TGF-β,
GM-CSF, PGE2, B7-H1, PD-1, and Arginase I), (c) func-
tionally impaired immune cells, and (d) tumor-associated
macrophages (TAMs) and their mediators such as nitric
oxide which eﬀectively halts the antitumor immunity [45].
The intracellular milieu is a challenging aspect for any
immunotherapy including Lm-LLO-based immunotherapy.
Figure 2 summarizes some of the in vivo events manifested
by Lm-LLO-based immunotherapy which have the ability to
neutralize and/or reverse cell functions and mediator release
involved in tumor immunity. Much of these events are also6 Journal of Oncology
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Figure 3: A schematic representation of the plasmid pActA-E7. The
recombinant plasmid was used to transform the Lm strain XFL-7
to create Lm-ActA-E7. The vector includes a promoter (pHly)a n d
signal sequence (ss) from the hly gene, the actA gene, the human
papillomavirus 16 E7 gene, and the transcription factor prfA.X F L -
7i saprfA-deleted strain of Lm. Thus, only bacteria that retain the
plasmid will replicate in vivo. Adopted and modiﬁed from [49].
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Figure 4:Lm-ActA-E7causesregressionofestablishedTC1tumors.
C57BL/6 mice received 2 × 105 TC1 cells subcutaneously on the
left ﬂank. Tumors grew to 5mm after 7 days. The mice were then
treated with 0.1 median lethal dose of Lm-ActA-E7 or Lm-LLO-NP
( d a t an o ts h o w n )a san e g a t i v ec o n t r o lo nd a y7 ,a n dab o o s t e rd o s e
was given on day 14. The third and ﬁnal group was left untreated.
The average tumor diameter was measured with calipers and is
shown for each mouse. The diﬀerence in tumor sizes between the
Lm-ActA-E7 group and either control group at days 20 and 28 is
statistically signiﬁcant (P ≤ .005 and P ≤ .001, resp.). Depicted is 1
experiment representative of 4. The ﬁgure and legend were adopted
and modiﬁed from [49].
induced in the animal model of E7-induced tumors dur-
ing Lm-LLO-HPV-induced immunotherapy. For example,
studies by Advaxis and Paterson Lab showed a correlation
between CD8+ T-cell induction, tumor homing, and the
antitumor eﬃcacy of the Lm-LLO-based immunotherapy
[20].
The eﬀect on diﬀerent T-cell populations in tumor mi-
croenvironment after treatment with Lm-E7 and Lm-LLO-
E7 in mice harboring TC1 tumors is shown in Table 2.
There was an increase in TILs and a decrease in CD25+
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Figure 5: Lm-ActA-E7 induces E7-speciﬁc cytotoxic T-lymphocyte
(CTL) activity. C57BL/6 mice were immunized with 0.1 median
lethal dose of Lm-ActA-E7 or Lm-LLO-NP. A separate group of
mice was left untreated. A booster immunization was administered
7 days later. Splenocytes were harvested 7 days after the booster
and established in primary culture with irradiated TC1 cells for 7
days. Following the primary culture, CTL activity was assayed via
chromium 51 (51Cr) release from EL4-E7 cells. The CTL activity
was signiﬁcantly higher in those mice that were vaccinated with
Lm-ActA-E7 than in controls (P ≤ 0.05). Results are expressed as
the mean of triplicate cultures. These results are representative of 3
e x p e r i m e n t s .T h eﬁ g u r ea n dl e g e n da r ea d o p t e df r o m[ 49].
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Figure 6: Eﬀect of ampicillin treatment on therapy of TC1 by
ADXS11-001. C57BL/6 mice were injected with 1 × 105 TC1
tumor cells. Seven days later, the mice were treated with 0.1 ×
LD50 of ADXS11-001. Beginning 3, 5, or 7 days after ADXS11-001
treatment, some of the mice received daily injections of 10mg of
Ampicillin, delivered for three consecutive days; the mice were then
maintained on drinking water supplemented with Ampicillin at a
concentration of 0.5mg/mL. The data is adopted from [17].Journal of Oncology 7
Table 2: Lm-LLO-based immunotherapy increases CD8+ T cells (TILs) and decreases CD25+CD4+FoxP3+ Tregs in tumor. Comparison of
CD8+ T cells (TILs) and CD25+CD4+FoxP3+ Tregs in TC1 mouse tumor after treatment with Lm-E7 or Lm-LLO-E7. The data has been
adopted and modiﬁed from Shahabi et al. [17].
Immunotherapy group E7/Db tetramer positive activated
CD8+ Tc e l l si nt u m o r s( T I L s )
CD25+CD4+FoxP3+
Tregs in the tumor CD8+ TIL:Tregs ratio
Lm-E7 9.4% 11.8% 0.80
Lm-LLO-E7 36.8% 1.7% 21.65
Table 3: Percent of intratumoral Tregs in a TC1 model following
treatment with Lm-E7 and Lm-LLO-E7 in mouse model of cervical
cancer [20].
Percent intratumoral Tregs by vector type
Lm-E7 Lm-LLO-E7
Spleen Tumor Spleen Tumor
6.4 12.1 4.5 2.3
7.0 12.2 3.9 2.0
6.9 14.9 4.5 1.1
6.5 8.9 3.9 1.3
CD4+FoxP3+ Tregs in tumors of mice immunized with Lm-
LLO-E7 suggesting that LLO-E7 fusion not only increases
T-cell inﬁltration but also reduces suppressive cells intra-
tumorally. In order to determine if similar eﬀect on Tregs
was observed in the periphery, the distribution of these cells
was monitored in the spleen. As shown in Table 3 treatment
with Lm-LLO-E7 vaccine causes a preferential decrease in
the Tregs intratumorally and has no eﬀect on the periphery
such as spleen. These studies show that Lm-LLO-based
immunotherapies cause speciﬁc reduction of Tregs within
the tumor to stimulate antitumor immunity.
The fusion of antigens to LLO also appears to facilitate
thesecretionoftheantigen[7,32]andincreasedantigenpre-
sentation with a profound inﬂuence on the CD8+ T-cell acti-
vation [50]. Lm-LLO-Ag reduces the percentage of immune-
suppressive Tregs inﬁltrating the tumor and helps to stim-
ulate the maturation of DCs and other myeloid cells [44].
Singh et al. have shown a decrease in MDSC to play a critical
role in tumor regression with Lm-LLO-based immunother-
apy in mouse cancer models (unpublished data. Advaxis,
Inc.). Previous studies have reported accumulation of Lm
within the tumor during immunotherapy [20]. Lm-based
vaccines have been reported to infect the primary tumor and
metastases tumor in vivo [51]. Kim et al. [51] suggested that
Lm vaccines could kill tumors (a) by directly infecting the
tumor and increasing the levels of ROS and (b) by directing
CTL responses against cells expressing speciﬁc antigens.
Preclinical studies demonstrate that Lm-LLO-based
immunotherapy encompasses a coordinated and compre-
hensive cellular reaction towards tumor destruction in E7-
induced tumors in mouse models. These preclinical data
show that Lm-LLO-based immunotherapy is pleotropic in
nature and has many of the traits required for overcoming
the central and peripheral immunological tolerance that is
exerted in the tumor microenvironment described above.
Furthermore, Lm-LLO-based immunotherapy is antigen,
tissue speciﬁc, and unlike chemotherapy, once the tumor is
eradicated, it persistently blocks its reoccurrence in mouse
models of cancer due to the development of immunological
memory. These experiments also demonstrated the eﬃcacy
ofLm-LLO-basedimmunotherapytoatumorthatisinduced
by a viral oncogene.
11. ClinicalDevelopment Planfor
ADXS11-001
The most likely diseases to evaluate the safety and eﬃcacy
of ADXS11-001 are cervical intraepithelial neoplasia (CIN)
and cervical cancer, HPV-positive head and neck cancer,
and perhaps other HPV-associated diseases like vulvar
intraepithelial neoplasia (VIN), and even lung and colorectal
cancer where an HPV link can be identiﬁed. To date, a Phase
1 study has been completed, two Phase 2 trials are ongoing,
and 2 additional Phase 2 trials currently await institutional
approval to begin.
11.1. Phase 1 Study. A Phase 1 trial of ADXS11-001 was
conducted in 15 patients with previously treated metastatic,
refractory, or recurrent cervical cancer who had failed
previous cytotoxic therapy [19] and in a population where
no therapeutic regimen had been shown to extend survival.
ADXS11-001 was administered by intravenous infusion at
three (3) dose levels (1 × 109 CFU, 3.3 × 109 CFU, and 1 ×
1010 CFU) using a dose escalation design across cohorts with
each patient in a cohort receiving only two administrations
of the same dose. The infusion was administered to each
study participant over 30 minutes and occurred once every
21 days for a total of two treatments on days 1 and 22,
respectively. Overall, 15 (100%) of patients experienced
cytokine-mediated adverse events (AEs). The most com-
monly reported AEs were pyrexia, chills, anemia, headache,
vomiting, nausea, tachycardia, and musculoskeletal pain.
Drug-relatedAEsweremildtomoderate,transientinnature,
and consisted of “ﬂu-like” symptoms such as pyrexia, vom-
iting, chills, headache, tachycardia, and nausea and which
responded to standard nonprescription agents. Infusion of
1 × 1010 or more CFU without premedication resulted in a
doselimitingtoxicity(DLT)ofGrade2diastolichypotension
occurring within hours after the ADXS11-001 infusion
that required therapeutic intervention. In all patients, the
hypotension was successfully controlled with IV ﬂuids and
supporting medication. Similar DLT have been observed at
1 × 1010 for other live Lm-based vectors in trials conducted
by other sponsors [19]; therefore, doses of 1 × 109 CFU or
less were selected for subsequent clinical evaluation.8 Journal of Oncology
Historically, the median survival of these patients is ap-
proximately 6 months with a one-year survival of 5%
(unpublished data (GOG 127 series Phase 2 studies)). In the
Phase 1 study of ADXS11-001, 4 of 13 evaluable patients
experienced a reduction of their tumor burden; median
survival was 347 days, and one-year survival was 53%.
11/15 patients (73%) had a performance status ECOG 2–
4. The clinical beneﬁt of increased survival and tumor
shrinkage observed in this advanced malignancy setting
merited further investigation.
11.2. Phase 2 Studies. Most immunotherapies seem to work
best in earlier stages of disease where the tumor burden
is lower and there has been less prior therapy. In the case
of HPV-associated cervical cancer, there is a clear and
slowly progressing maturation of dysplasia toward cervical
cancer known as CIN. Frequent Pap smears and colposcopic
examination can identify subjects with CIN. The standard
of care for high-grade CIN (CIN 2/3) is a surgical resection
of the dysplastic tissue in the cervix. While this is typically
an outpatient procedure, it can compromise future fertility
of the woman and recurrence can occur. There is also a
signiﬁcant spontaneous remission rate in women with CIN
which is inversely proportional to the grade of their CIN.
An agent that can induce immunologic remission of high-
grade cervical dysplasia could eliminate the risks associated
with surgery and provide immunologic memory that could
in theory protect against recurrence.
Lm-LLO-E7-07 is a randomized, single blind, placebo-
controlled, dose escalation Phase 2 trial being conducted in
the US in 120 women with CIN 2/3. The initial 40 subject
cohort has been completed with 31 subjects receiving 80
doses.Eachsubjectreceived3doseseachofdose5 ×107 CFU
or placebo (3:1 randomization). Enrollment of the second
cohort is ongoing.
Lm-LLO-E7-015 is a randomized Phase 2 trial being con-
ducted in India in women with progressive cervical cancer
who have failed cytotoxic therapy. Patients are randomized
to 3 doses of ADXS-011 at 1 × 109 CFU or 4 doses of 1 ×
109 CFU with cisplatin chemotherapy between doses 1 and
2. As of 8/1/11, 54 patients have received 117 doses.
In both studies, Naprosyn and oral promethazine are
given as premedications to ameliorate potential side eﬀects,
and a course of ampicillin is given 3 days after infusion as
a precautionary measure. From this clinical experience, a
clearpatternoftreatment-relatedadverseeventshasemerged
consisting of fever, chills, nausea, and vomiting which
are consistent with the release of immunologic cytokines
commonly associated with immune activation. Between 15
and23%ofthedosesadministeredhavebeenassociatedwith
a drug-related adverse event; typically a transient Grade 1 or
2 (mild-moderate) ﬂu-like symptom, which appears within
a few hours to 3 days after infusion. Symptoms either self-
resolve or respond quickly to symptomatic treatment. Thus
far, there have been no serious adverse events associated
with ADXS11-001 in 171 doses, no evidence of listeriosis, no
persistentsymptoms,nodelayedsymptoms,andnoevidence
of cumulative toxicity in subsequent doses.
A GOG Phase 2 trial in the US in patients with
recurrent/refractory cervical cancer and a Phase 1/2 safety
and eﬃcacy of ADXS11-001 in HPV-positive oropharyngeal
head and neck cancer were funded by Cancer Research UK
(CRUK).
12. Conclusion
ADXS-11-001 immunotherapy can be safely administered
to healthy young subjects as well as patients with advanced
cancer and presents a predictable and manageable safety
proﬁle. This agent has the capability of inducing the
type of immunologic response that has been observed
in cases of spontaneous remission and responding HPV-
transformed lesions. ADXS-11-001 can generate a Th-1 type
immunologic response generating CD8+ T cells that target
HPV-E7-transformed cells while simultaneously suppressing
the Treg- and MDSC-driven immunologic tolerance within
the lesions, increasing the CD8/Treg(FOX P3+) ratio, and
causing clinical remission. Clinical trials are ongoing to
evaluate the activity of this agent across the spectrum
of diseases caused by HPV transformation from cervical
intraepithelial neoplasia (CIN 2/3) through locally advanced
cervical cancer to advanced recurrent cervical cancer. Other
HPV-associated malignancies are also being investigated or
are of interest including HPV-positive head and neck cancer
and types of lung and colorectal cancer where an HPV link
can be identiﬁed.
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